Clinical Trial

A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in patients with MSA.
Protocol Amendment History 2 changes
minor Completion pushed: 2027-01-01 -> 2027-10-31 2026-06-30
notable Sponsor changed: Ono Pharmaceutical Co. Ltd -> Ono Pharmaceutical Co., Ltd. 2026-04-19
Trial Details
NCT Number NCT05923866
Lead Sponsor Ono Pharmaceutical Co., Ltd.
Conditions Multiple System Atrophy (MSA)
Enrollment 92 participants
Start Date 2023-09-22
Primary Completion 2025-09-15 (estimated)
Study Completion 2027-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-29